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Background: Human 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) formally
known as aldo-keto reductase 1C3 (AKR1C3) play a major role in the formation and metab-
olism of androgens. The enzyme is highly expressed in the prostate gland and previous
studies indicate that genetic variation in the AKR1C3 gene may influence the prostate vol-
ume and risk of prostate cancer.Aim:Here we aimed to further study the genetic regulation
of AKR1C3 and its putative role in prostate cancer. Experiments: A previously identified
promoter polymorphism (A>G, rs3763676) localized at −138 from the translational start
site were studied in relation to prostate cancer in a Swedish population based case–control
study including 176 patients diagnosed with prostate cancer and 161 controls. Moreover,
we have studied the basal and androgen induced promoter activity of the AKR1C3 gene.
Expression studies with AKR1C3 promoter reporter constructs were performed in HepG2
and DSL2 cells. Results:We found that carriers of the promoter A-allele had a borderline
significant decreased risk of prostate cancer (OR=0.59; 95% CI=0.32–1.08). We also
show that dihydrotestosterone (DHT) induced the promoter activity of the A-allele 2.2-fold
(p=0.048). Sp3 seem to play an important role in regulating the transcription activity of
AKR1C3 and site-directed mutagenesis of a GC-box 78 base-pair upstream the ATG-site sig-
nificantly inhibited the basal AKR1C3 promoter activity by 70%. Conclusion:These results
further supports previous findings that the A>G promoter polymorphism may be functional
and that AKR1C3 plays a critical role in prostate carcinogenesis. Our findings also show
that the members of Sp family of transcription factors are important for the constitutive
expression of AKR1C3 gene.
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INTRODUCTION
Human 17β-HSD type 5 belongs to the aldo-keto reductase (AKR)
superfamily (Jez et al., 1997) and is formally known as AKR1C3. It
is a promiscuous enzyme that participates in the biosynthesis and
metabolism of a variety of substrates including androgens, estro-
gens (Penning et al., 2000), prostaglandins (Matsuura et al., 1998),
and polycyclic aromatic hydrocarbons (PAH; Palackal et al., 2002).
AKR1C3 is widely expressed in human tissues and is predominant
in the prostate and mammary gland (Penning et al., 2000).
The 17-keto reductase activity of AKR1C3 reduces the weak
androgen ∆4-androstenedione (4-dione) to testosterone. The
combined 3α/3β activity of the enzyme (Steckelbroeck et al., 2004)
partly inactivates 5α-dihydrotestosterone (DHT) to the weak
androgens 3α-androstanediol (3α-Adiol) and 3β-androstanediol
(3β-Adiol) and the 17β-hydroxysteroid oxidase activity of the
enzyme oxidizes 3α-Adiol to androsterone instead of back to DHT
(Penning et al., 2000).
The prostate gland is generally considered an important site
of DHT formation and inactivation (Thigpen et al., 1993). DHT
stimulates the proliferation of the prostate and AKR1C3 has been
shown to be up-regulated in localized and advanced prostate ade-
nocarcinoma (Nakamura et al., 2005; Fung et al., 2006; Stanbrough
et al., 2006).
Previously an A>G polymorphism in the promoter region
(rs3763676) at nucleotide position−138 from the translation start
site was identified (Qin et al., 2006). The G-allele has been associ-
ated with lower promoter activity in human liver (HepG2), lung
(A549), and prostate (LNCaP) cells (Jakobsson et al., 2007) and
higher promoter activity in rat theca cells (Qin et al., 2006). The
allele frequency of this SNP was shown to be significantly increased
in patients with polycystic ovary syndrome (PCOS; Qin et al.,
2006) and increased risk for bladder cancer (Figueroa et al., 2008)
whereas its involvement in prostate cancer has not been studied.
Previous studies of the AKR1C3 promoter have shown that
a 169-bp region (−104 to +65) is capable of directing tran-
scriptional activity (Ciaccio et al., 1996). This 5′-flanking region
contains a CTT-repeat element, two GC-boxes, and a reverse
CCAAT-box. The GC- and CCAAT-boxes generally work as pro-
moter signals in many eukaryotic cells. There is one study showing
the Sp family of transcription factors play an important role
in regulating constitutive expression of the AKR1C3 (Qin and
Rosenfield, 2005).
The overall aim of this study is to increase the understand-
ing on how AKR1C3 is genetically regulated and its putative role
in prostate cancer. More specifically the aims of this study are to
investigate (1) the influence of the CCAAT and the GC-elements
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on the basal expression of the human AKR1C3 gene in HepG2
cells, (2) investigate if DHT affect the transcriptional activity of
AKR1C3 in relation to the promoter A>G polymorphism, and (3)
the allele frequency of this promoter SNP in relation to risk for
prostate cancer in a Swedish population.
MATERIALS AND METHODS
SITE-DIRECTED MUTAGENESIS
Mutations in the CCAAT and GC-boxes were introduced using the
pGLAKR1C3prom construct (Jakobsson et al., 2007) as template
and the antisense primers (5′-gatggttaacatctggcatgtag-′3) and (5′-
gaaacccctcccaacacccctg-′3) including the mutations together with
a sense primer (5′-ggttgctatttgttctacaaa-′3). The PCRs were per-
formed in 2 mM MgCl2, 0.15 mM dNTP, 0.3µl Taq Polymerase,
20 pmol of each primer, 100 ng of template, and were carried out
in 30 cycles, each involving denaturing at 94˚, 45 s, annealing at
53˚, 45 s, elongation at 72˚, 1 min, followed by 7 min elongation.
The PCR products were gel-purified (Qiagen) and used as a mega
primer together with an antisense primer (5′-cattccctgtcacttgtctg-
′3) in a second PCR. The product was subcloned into a TA-vector
(Invitrogen) and cleaved with the restriction enzymes, XhoI and
Kpn1 (New England BioLabs), gel-purified, and subcloned into
similar digested pGL3 Basic vectors (Promega). All the mutations
were verified by sequence analysis.
CELL CULTURE
Human hepatoma HepG2 cells were maintained at 37˚C in 5%
CO2 in MEM, 10% bovine serum, 2 mM glutamine, 1 mM sodium
pyruvate, non-essential amino acids, 100 U penicillin, and 100µg
streptomycin/ml.
Drosophila DSL2 cells were maintained at room temperature in
Schneider’s Medium, 10% bovine serum, 2 mM glutamine, 100 U
penicillin, and 100µg streptomycin/ml.
All cell culture media and their ingredients were obtained from
GIBCO/BRL (Gaithersburg, MD, USA).
TRANSFECTION ASSAY
HepG2 cells were plated in 35 mm 6-well plates at 2× 105/well
and incubated overnight. The cells were transfected using 15µl
Lipofectin (Life Technology), 2.5µg pGLAKR1C3 Basic plasmid,
and 2.5µg β-gal control vector (Promega). Cells were incubated
for 5 h at 37˚C, the transfection solution was then replaced with
fresh media. DSL2 cells were plated in 36 mm 6-well plates at
2× 106 cells/well at the day of transfection. Two micrograms of
pGLBasicAKR1C3 plasmid, 2.5µgβ-gal control vector (Promega),
0.5–1.5µg of Sp1, and/or Sp3 expression vectors (pPACSp1 and/or
pPACSp3 kindly provided by Dr. Ahmed Zaid) and 10µl Super-
fect (Qiagen) were used in each transfection reaction. Cells were
incubated for 3 h at room temperature, the transfection solution
were then replaced with fresh media. Cells were harvested 48 h
after transfection and luciferase activity was determined using
luciferase assay reagent (Promega). βgal activity was measured
using ortho-nitrophenyl β-d-galactopyranoside (Sigma) as a sub-
strate. All values were corrected for endogenous galactosidase
activity. The luciferase values were divided by the βgal value in
order to correct for transfection efficiency.
REAL-TIME PCR
Total RNA was extracted from DHT exposed HepG2 cells with Tri-
zol reagent (Invitrogen) according to the manufacturers manual.
1µg RNA was reverse transcribed using First-strand cDNA Syn-
thesis Kit (Amersham) with a random hexamer oligonucleotide.
Real-time PCR was performed using 1µl cDNA, 10 pmol AKR1C3
specific primers (Bogason et al., 2011), SYBR Green (Applied
Biosystems), and quantified in an ABI Prism 700. Dilutions of a
plasmid containing AKR1C3 cDNA (19T7-AKR1C3Glu77; Jakob-
sson et al., 2007) was used to construct a standard curve. For
normalization of cDNA input in each PCR, 18S mRNA was used
as an endogenous control.
HUMAN STUDY
In another part of the study a population based case–control study
of 337 Caucasians living in the county of Örebro in Sweden were
investigated. The cases were 176 patients, age 51–79 years, with
prostate cancer, who were recruited consecutively between May
1994 and February 1996. In all, 81% agreed to participate. The
controls were men, who were randomly selected every 3 months
from the county population register and frequency matched for
age. They were asked to participate by mail and 161 individu-
als agreed to participate, giving a response rate of 79%. Further
description of the study population has been already published
since this study population has been utilized in the evaluation
of other polymorphisms involved in the androgen metabolism
(Wadelius et al., 1999; Söderström et al., 2002). The Ethics Com-
mittee of the Regional Hospital of Örebro/Uppsala University,
Sweden approved the study and all patients gave informed consent
to participate. Genotyping of the A>G promoter polymorphism
was performed as described previously (Jakobsson et al., 2007).
DATA ANALYSIS
Data of promoter activity and real-time PCR are expressed as
mean± SD Significance was assessed using two-tail Student’s t -
test using GraphPad Prism software v4.03 (San Diego, CA, USA).
Genotype associations were assessed with binary logistic regres-
sion using Minitab statistical software package (v 12.1, Minitab
Inc., State College, PA, USA). ORs were used as an approximation
of relative risk, using 95% confidence intervals.
RESULTS
FUNCTIONAL ANALYSIS OF HUMAN AKR1C3 BASAL PROMOTER
ACTIVITY
Transfection assay with wildtype and mutant reporter constructs
were performed in HepG2 cells to study the effect of the CCAAT-
and GC-box mutations on luciferase activity. Mutation of the
CCAAT-box did not inhibit the promoter activity in HepG2,
instead a borderline (p= 0.06) significant 50% increase was
observed (Figure 1).
Transfections with the reporter construct including a mutated
GC-box indicate that the promoter activity decreased significant
(70%, p< 0.05) in HepG2 cells (Figure 1). These results indi-
cate that the GC-box is important for directing and activating the
transcription of the AKR1C3 gene in HepG2 cells.
Transfections with the wildtype promoter construct in DSL2
cells show that when increasing concentrations of Sp3 (0.5, 1.0, and
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery August 2012 | Volume 3 | Article 151 | 2
Schulze et al. AKR1C3 promoter studies
FIGURE 1 | HumanAKR1C3 promoter fragment was subcloned into the
pGL3 Basic vector and the CCAAT- and GC-elements were mutated
and transiently transfected into HepG2 cells.The bar graph represents
mean±SD from at least three experiments. The luciferase expression was
normalized to the transfection efficiency by β-galactosidase expression.
When the CCAAT-box was mutated there was a borderline significant 50%
increase in the relative luciferase activity. When the GC-box was mutated
the luciferase activity significantly decreased indicating that the GC-box is
required for the basal transcription of the AKR1C3 gene in HepG2 cells.
1.5µg) were added to the cells, the promoter activity increased 1.5
times, whereas no activation of the basal activity of shown when
increasing concentrations (0.5, 1.0, and 1.5µg) of Sp1 were added
(Figure 2A).
When Sp3 was added at 1µg the addition of Sp1 (1µg) did not
further activate the promoter activity, whereas a Sp3 induced the
promoter activity 2.2 (p< 0.05) times when added together with
Sp1 (Figure 2B).
These results indicate that both the Sp1 and Sp3 proteins are
involved in the transcription of AKR1C3 gene, although the Sp3
seem to be the most important protein.
STEROID AND PROMOTER ACTIVITY IN RELATION TO PROMOTER
POLYMORPHISM
When the HepG2 cells were exposed to high concentration
(25µM) of DHT over night the promoter activity of the wild-
type (A) construct increased 2.2-fold (p= 0.048), whereas for
the polymorphic construct (G) there were no significant induc-
tion observed (Figure 3A). When HepG2 cells were exposed to
DHT a significant sevenfold increase of the AKR1C3 mRNA levels
(p= 0.038) was found (Figure 3B).
PROMOTER POLYMORPHISM AND PROSTATE CANCER RISK
The distribution of the promoter polymorphism was in Hardy–
Weinberg equilibrium. The allele frequency of the promoter poly-
morphism G in healthy participants were 39% (Table 1), as in
agreement with previous studies in Caucasians (Jakobsson et al.,
2007). Individuals displaying an A-allele (A/G and A/A) showed
0.59 times decreased risk for prostate cancer compared to individ-
uals homozygous for the G-allele (Table 2). The results were quit
not significant (p= 0.058).
DISCUSSION
To evaluate the possible role for AKR1C3 in prostate cancer,
a promoter polymorphism (A>G, rs3763676) were genotyped
in a population based case–control study. The result indicates
that the promoter SNP in the AKR1C3 gene may modulate the
prostate cancer risk and that there may be an advantage to
have an A-allele. The results are in agreement with our in vitro
finding that the promoter activity of the wildtype A variant is
induced by DHT and with our previous finding that the G-
variant displayed lower transcription activity in a prostate can-
cer cell line (Jakobsson et al., 2007). AKR1C3 is an important
enzyme in the metabolism of DHT, particularly in the inactiva-
tion of DHT to the less potent androgen 3α-Adiol (Lin et al.,
1997). It is possible that A-carriers may have an improved pro-
tection against high concentrations of DHT since this allele is
correlated with higher transcriptional activity, and is induced by
DHT. Contradictory to this hypothesis, i.e., that high expres-
sion of AKR1C3 is protective against androgen load, is a study
by Stanbrough et al. (2006) who found a 5.2-fold increase of
AKR1C3 mRNA level in androgen-independent prostate cancer
bone metastasis.
Recent studies have shown that another AKR1C3 polymor-
phisms (c90 G/A (rs7741), known to be in linkage disequilibrium
with the A>G promoter polymorphism (R2= 1; International
HapMap Consortium, 2005), is associated with prostate disease.
The c90 A-allele has been associated with increased risk for prostate
enlargement (Roberts et al., 2006), and increased risk of both
familial and sporadic prostate cancer. (Cunningham et al., 2007).
Additionally, another AKR1C3 SNP (rs4881400), not in linkage
disequilibrium with the promoter polymorphism, has been asso-
ciated with prostate cancer risk (Kwon et al., 2012). Thus it is likely
that AKR1C3 play a role in the etiology of prostate related diseases.
Whether the promoter polymorphism investigated in this study is
associated with prostate cancer risk needs to be further investi-
gated in larger prostate cancer case–control studies. The fact that
the promoter SNP studied herein is included in common GWAS
analysis such as Affymetrix SNP 6.0, will increase the chance to
find such association.
In agreement with our results, one study found that the G-
allele was significantly more frequent in women with PCOS.
Like prostate cancer, PCOS is also considered to be an androgen
dependent disease, and the authors speculated that the increased
risk may be due to higher plasma testosterone levels in sub-
jects homozygous for G-allele (Qin et al., 2006). However, a
subsequent study were not able to find an association between
the promoter A>G polymorphism and PCOS (Goodarzi et al.,
2008).
Here we show that DHT increase the promoter activity of the
AKR1C3 promoter including the wildtype (A) sequence, whereas
the polymorphic G-variant was not up-regulated in HepG2 cells.
Moreover, the AKR1C3 mRNA level was induced sevenfold after
DHT exposure in HepG2 cells. This finding was not in agreement
with a study performed in LNCaP cells, where DHT was shown
to decrease the expression of AKR1C3 by 70% (Wang and Tuo-
himaa, 2007). This discrepancy of may be due to the different
DHT concentrations used (10 nM versus 25µM) in the studies.
The former concentration is reflecting the physiological of DHT
in the circulation, whereas the supra-physiologic concentration
of 25µM reflects the high levels of DHT produced locally in the
prostate (Olsson et al., 2011). Moreover, the androgen response
may differ between the cell-lines used. Further investigations are
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FIGURE 2 | (A)Transcriptional activities of the AKR1C3 promoter construct
transiently transfected into DSL2 cells. The DSL2 cells were cotransfected
with Sp-proteins in increasing concentrations. The bar graph represents
mean±SD from at least three experiments. The luciferase expression was
normalized to the transfection efficiency by β-galactosidase expression.
Control background activity was increased twofold when Sp3 (0.5, 1, and
1.5µg) were added to cells, whereas no significant affect was observed when
increasing concentrations of Sp1 were added. (B) Human AKR1C3 promoter
construct was transiently transfected into HepG2 cells cotransfected with
Sp1/Sp3 proteins. The bar graph represents mean±SD from at least three
experiments. The luciferase expression was normalized to the transfection
efficiency by β-galactosidase expression. When the Sp1 protein (1µg)
containing DSL cells were cotransfected with Sp3 (1.5µg) the promoter
activity increased 2.2-fold. When the Sp3 (1µg) containing DSL cells were
cotransfected with Sp1 (1.5µg) no induction in promoter activity was
observed.
FIGURE 3 | (A)The HepG2 cells were transfected with the wildtype
AKR1C3 promoter (A) and the polymorphic (G) construct and exposed to
25µDHT over night. The bar graph represents mean±SD from at least
three experiments. The luciferase expression was normalized to the
transfection efficiency by β-galactosidase expression. After DHT
treatment and promoter activity of the wildtype (A) significantly
increased whereas no significant alteration was observed for the
polymorphic (G) construct. (B)The mRNA expression of the human
AKR1C3 gene in HepG2 cells was evaluated using real-time PCR.
Significant increase in AKR1C3 mRNA levels was observed after
incubation with 25µM DHT over night. The bar graph represents
mean±SD from four experiments.
Table 1 | Genotype and allele frequencies of the promoter
polymorphism (A>G) in a Swedish population sample of prostate
cancer and controls.
Cases Controls
% (n) % (n)
AA genotype 40 (71) 39 (63)
GG genotype 19 (33) 12 (19)
AG genotype 41 (72) 48 (77)
required to evaluate how androgens modulate expression and
activity of AKR1C3 in different cell types, particularly in androgen
sensitive cells.
In order to study the cis-acting elements involved in the
AKR1C3 basal promoter activity we transfected the promoter
wildtype and two mutated (CCAAT- and GC-elements) promoter
construct in HepG2 cells. The result indicates that the inverted
Table 2 | Prostate cancer risk estimates for AKR1C3 A/G promoter
polymorphism among Swedish Caucasian men.
Genotype Odds ratio 95% CI
G/G 1.00 Ref.
A/G 0.54 (0.28–1.03)
A/A 0.65 (0.34–1.25)
A* 0.59 (0.32–1.08)
*All carriers of A compared to homozygous carriers of G.
CCAAT-box is not involved in the basal transcription of AKR1C3.
Instead binding to the CCAAT-box may have an inhibitory effect
on the AKR1C3 expression since we observed an increase in pro-
moter activity when this element was mutated. The GC-box on
the other hand appears to be involved in the constitutive expres-
sion. The GC-boxes are GC rich sequences recognized by the
Sp transcription factor family (Kingsley and Winoto, 1992). To
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further examine the trans-acting proteins involved in the AKR1C3
transcription, the wildtype promoter construct was transfected
into DSL2 cells. DSL2 cells are used to specifically study the Sp fam-
ily of transcription factors since these cells lack Sp-proteins. When
constructs were added to the cells without the Sp1/Sp3 expression
vectors, a low background activity was observed. The addition of
Sp3 increased the expression, whereas the addition of Sp1 alone
did not induce the promoter activity. Co-transfection with Sp1
and Sp3 proteins also indicate that Sp3 may have a more impact
on the promoter activity compared to Sp1.
Previous studies of the AKR1C3 promoter have shown that
a 169-bp region (−104 to +65) is capable of directing tran-
scriptional activity (Ciaccio et al., 1996). This 5′-flanking region
contains a CCT repeat element, 2 GC-boxes and a reverse CCAAT-
box. Qin and Rosenfield (2005) showed that the binding of
Sp1/Sp3 to the CCT repeat element was important for the con-
stitutive and forskolin stimulated AKR1C3 promoter activity in
H295R cells. The GC- and CCAAT-boxes generally work as pro-
moter signals in many eukaryotic cells. The GC-boxes are GC rich
sequences recognized by the Sp transcription factor family (Kings-
ley and Winoto, 1992). Our results together with Qins (Qin and
Rosenfield, 2005) clearly show that the transcription of AKR1C3
gene is driven by Sp-proteins.
In conclusion, our results further support previous findings
that AKR1C3 play an important role in the androgen metabolism
and in the etiology of prostate cancer.
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